-
![METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS](/abs-image/US/2015/09/10/US20150250775A1/abs.jpg.150x150.jpg)
31.发明申请METHODS OF USING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID FOR TREATMENT OF ANTECEDENT HEMATOLOGIC DISORDERS 有权使用（+） - 1,4-二氢-7 - [（3S，4S）-3-甲氧基-4-（甲基氨基）-1-吡咯烷基] -4-氧代-1-（2-噻唑烷基）-1 ，8-萘基-3-羧酸用于治疗遗传性血液病公开(公告)号：US20150250775A1
公开(公告)日：2015-09-10
申请号：US14517535
申请日：2014-10-17
Applicant: SUNESIS PHARMACEUTICALS, INC.
Inventor： Glenn Michelson
IPC: A61K31/4375 , A61K38/19 , A61K39/395 , A61K38/18 , A61K31/7068 , A61K31/706
CPC classification number: A61K31/4375 , A61K31/513 , A61K31/706 , A61K31/7068 , A61K38/18 , A61K38/19 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/54 , C07D471/04 , A61K2300/00
Abstract: Methods of treating, preventing or managing antecedent hematologic disorders, such as myelodysplastic syndrome, including chronic myelomonocytic leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cytarabine. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.
Abstract translation: 公开了治疗，预防或治疗先天性血液病的方法，例如骨髓增生异常综合征，包括慢性骨髓单核细胞白血病。 这些方法包括SNS-595的管理。 还提供了使用化合物与化疗，放射治疗，激素治疗，生物治疗或免疫治疗的治疗方法。 在某些实施方案中，治疗方法包括与阿糖胞苷组合施用SNS-595。 还公开了适用于该方法的药物组合物和单一单位剂型。
-
公开(公告)号：US20150158843A1
公开(公告)日：2015-06-11
申请号：US14406315
申请日：2013-06-07
Applicant: BIOGEN IDEC MA INC. , SUNESIS PHARMACEUTICALS, INC.
Inventor： Brian T. Hopkins , Patrick Conlon , Timothy R. Chan , Tracy J. Jenkins , Xiongwei Cai , Michael Humora , Xianglin Shi , Ross A. Miller , Andrew Thompson
IPC: C07D401/14
CPC classification number: C07D401/14
Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
Abstract translation: 本发明提供了可用作Bruton酪氨酸激酶抑制剂的化合物及其组合物，并且其表现出所需特性。
-
公开(公告)号：US20150080568A1
公开(公告)日：2015-03-19
申请号：US14444007
申请日：2014-07-28
Inventor： Weirong Chen , Benjamin Lane , Hairuo Peng
IPC: C07D487/04 , C07D413/14 , C07D417/14
CPC classification number: C07D417/14 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D473/00 , C07D487/04 , C07F9/65583
Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.
-
公开(公告)号：US10577374B2
公开(公告)日：2020-03-03
申请号：US15698171
申请日：2017-09-07
Applicant: Sunesis Pharmaceuticals, Inc. , Biogen MA Inc.
Inventor： Minna Bui , Patrick Conlon , Julio H. Cuervo , Daniel A. Erlanson , Junfa Fan , Bing Guan , Brian T. Hopkins , Tracy J. Jenkins , Gnanasambandam Kumaravel , Alexey A. Lugovskoy , Doug Marcotte , Noel Powell , Daniel Scott , Laura Silvian , Art Taveras , Deping Wang , Min Zhong
IPC: C07D277/82 , C07D487/14 , C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D473/34 , C07D487/04 , A61K31/519
Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
-
公开(公告)号：US20190175589A1
公开(公告)日：2019-06-13
申请号：US16185793
申请日：2018-11-09
Applicant: Sunesis Pharmaceuticals, Inc.
Inventor： Gene Curtis JAMIESON
IPC: A61K31/4985 , A61K31/496 , A61K47/32 , A61K47/10 , A61K47/12 , A61K47/38 , A61K9/10 , A61P35/00
Abstract: The invention relates to pharmaceutical compositions, comprising a solid dispersion extrudate comprising any of certain active compounds that modulate cellular survival pathways implicating certain protein kinases, as described, for the treatment of cancer, and processes for the preparation of such compositions. The invention also relates to methods of administering such pharmaceutical compositions to patients for the treatment of cancer.
-
Patent Agency Ranking
公开(公告)号：US20190119268A1
公开(公告)日：2019-04-25
申请号：US15987523
申请日：2018-05-23
Inventor： Joseph ARNDT , Timothy CHAN , Kevin GUCKIAN , Gnanasambandam KUMARAVEL , Wen-Cherng LEE , Edward Yin-Shiang LIN , Daniel SCOTT , Lihong SUN , Jermaine THOMAS , Kurt VAN VLOTEN , Deping WANG , Lei ZHANG , Daniel ERLANSON
IPC: C07D471/04 , A61K31/498 , C07D213/82 , A61K31/444 , A61K31/452 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/5383 , A61K31/4985 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K31/437 , C07D498/04 , C07D241/28 , C07D519/00 , C07D491/052 , C07D487/04 , C07D473/34 , C07D417/14 , C07D409/14 , C07D409/04 , C07D405/14 , C07D403/14 , C07D403/12 , C07D401/14 , C07D401/12 , C07D241/26 , C07D213/85 , A61K31/4439
Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
-
公开(公告)号：US20190084978A1
公开(公告)日：2019-03-21
申请号：US15951061
申请日：2018-04-11
Applicant: Sunesis Pharmaceuticals, Inc.
Inventor： Anantha Sudhakar , Jeff Jacobs , Ahmad Hashash , Sean Ritchie , Hengqin Cheng
IPC: C07D471/04 , A61K31/4375 , C07D417/04 , C07D417/14
Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
-
公开(公告)号：US20190015410A1
公开(公告)日：2019-01-17
申请号：US15770369
申请日：2016-10-21
Applicant: Sunesis Pharmaceuticals, Inc.
Inventor： Stig K. HANSEN , Minke E. BINNERTS
IPC: A61K31/497 , A61P35/02
Abstract: Described are methods of use of compounds that inhibit PIF-mediated substrate binding by PDK1, which are useful as inhibitors of cancer growth or proliferation that is RSK2-dependent or AKT-independent. Also described are compositions of such compounds for use in such methods of treating cancer.
-
公开(公告)号：US20180370966A1
公开(公告)日：2018-12-27
申请号：US15876462
申请日：2018-01-22
Inventor： Kenneth Egnard LIND , Kathy CAO , Edward Yin-shiang LIN , Thinh Ba NGUYEN , Bradley T. TANGONAN , Daniel A. ERLANSON , Kevin GUCKIAN , Robert Lowell SIMMONS , Wen-cherng LEE , Lihong SUN , Stig HANSEN , Nuzhat PATHAN , Lei ZHANG
IPC: C07D471/04 , C07D409/12 , A61K31/4985 , C07D405/12 , C07D405/14 , C07D417/14 , C07D487/04 , C07D417/12 , C07D413/14 , C07D413/12 , C07D409/14 , C07D407/14 , C07D401/14 , C07D401/12 , C07D213/64 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/4412 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61K31/444 , C07D211/86
Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.
-
公开(公告)号：US09980949B2
公开(公告)日：2018-05-29
申请号：US14462439
申请日：2014-08-18
Applicant: Sunesis Pharmaceuticals, Inc.
Inventor： Michelle Arkin , Jennifer Hyde , Duncan Walker , Jasmin Wright
IPC: A61K31/4375 , A61K31/7048 , A61K45/06 , A61K38/15 , A61K33/24 , A61K31/7068 , A61K31/704 , A61K31/585 , A61K31/52 , A61K31/519 , A61K31/513 , A61K31/407 , A61K31/395 , A61K31/337 , A61K31/282
CPC classification number: A61K31/4375 , A61K9/0019 , A61K31/282 , A61K31/337 , A61K31/395 , A61K31/407 , A61K31/44 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/52 , A61K31/555 , A61K31/585 , A61K31/704 , A61K31/7048 , A61K31/7068 , A61K33/24 , A61K38/15 , A61K38/1816 , A61K41/00 , A61K45/06 , A61K47/12 , C07D471/04 , F24S10/70 , F24S50/40 , F24S60/30 , F24S80/60 , H01L31/0547 , H02S40/38 , Y02E10/40 , Y02E10/52 , A61K2300/00
Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.
-
-
-
-
-
-
-
-
-
Search Results
70
records
(took 0.049 seconds)
